Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives…
January 12, 2026 10:30 ET | Source: BridgeBio Pharma, Inc. - Preliminary unaudited Q4 and Full Year 2025 net Attruby® product…
January 11, 2026 13:00 ET | Source: Krystal Biotech, Inc. Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to…
- Rapidly transforming into a leading global biopharma company January 09, 2026 18:01 ET | Source: Ascendis Pharma COPENHAGEN, Denmark,…
December 29, 2025 16:30 ET | Source: iRhythm SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC),…
December 18, 2025 19:00 ET | Source: Mesa Laboratories, Inc. LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories,…
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading…